Stock 4547 KISSEI PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Kissei Pharmaceutical Co., Ltd.

Equities

4547

JP3240600001

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-04-26 am EDT 		5-day change 1st Jan Change
3,585 JPY +1.41% Intraday chart for Kissei Pharmaceutical Co., Ltd. +4.82% +16.02%
Mar. 20 Kissei Pharmaceutical Completes 6 Billion Yen Buyback Program MT
Mar. 19 Tranche Update on Kissei Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 8, 2023. CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kissei Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 2024
Kissei Pharmaceutical Repurchases 251 Million Yen Worth of Shares in December 2023
Kissei Pharmaceutical Co., Ltd. and Maruishi Pharmaceutical Co., Ltd. Announces KORSUVA®? IV Injection Syringe for Dialysis 17.5ug, 25.0ug to Launch in Japan for Treatment of Pruritus in Patients Undergoing Hemodialysis
Japanese Shares Close Lower on Tuesday After Key Economic Data
Kissei Pharmaceutical's Fiscal H1 Attributable Profit Surges as Net Sales Gains
Kissei Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024
Kissei Pharmaceutical Co., Ltd. Announces Second Quarter-End Dividend for the Year Ending March 31, 2024, Payable on December 4, 2023 and Provided Dividend Guidance for the Year Ending March 31, 2024
Kissei Pharmaceutical Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ending September 30, 2023
Kissei Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024
Kissei Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending March 31, 2024
Kissei Pharmaceutical Co., Ltd. Announces Withdrawal of Application for Marketing Approval for Rovatirelin for the Treatment of Spinocerebellar Degeneration in Japan
Kissei Pharmaceutical Co., Ltd. Introduces Iktos AI Drug Discovery System
The Hachijuni Bank, Ltd. completed the acquisition of the remaining 98.33% stake in The Naganobank, Ltd. from The Master Trust Bank of Japan, Ltd. (Trust Account), Custody Bank of Japan, Ltd. (Trust Account), The Tochigi Bank, Ltd., Kissei Pharmaceutical Co., Ltd.,Sompo Japan Insurance Inc. and others.
Kissei Pharmaceutical's Full-Year Profit Falls 18.5%
Kissei Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending March 31, 2024
Kissei Pharmaceutical Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 23, 2023; Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024
Kissei Pharmaceutical Co., Ltd. announces an Equity Buyback for 2,000,000 shares, representing 4.34% for ¥6,000 million.
Kissei Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023
Kissei Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
Kissei Pharmaceutical Co., Ltd. Launches TAVALISSE®? Tab. 100Mg and 150Mg, an Oral Spleen Tyrosine Kinase Inhibitor, in Japan for Chronic ITP
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4547 Stock
  4. News Kissei Pharmaceutical Co., Ltd.
  5. Other languages